ABIONYX Pharma: Monthly statement of total voting rights and shares making up the Company’s share capital

PARIS–(BUSINESS WIRE)–Regulatory news:

ABIONYX Pharma (Paris:ABNX):


Number of shares outstanding

Total voting rights

Gross total (1)

Net total (2)

July 31, 2022




(1) The total number of gross (or “theoretical”) voting rights serves as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all the shares to which voting rights are attached, including those whose voting rights have been suspended.

(2) The total number of net voting rights (or “exercisable at a General Meeting”) is calculated without taking into account the shares whose voting rights have been suspended. It is made public in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biotechnology company whose objective is to contribute to health through innovative therapies in indications where no effective or existing treatment exists, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholders, the company innovates on a daily basis to offer drugs for the treatment of kidney and ophthalmological diseases, or new HDL vectors used for the targeted delivery of medications.

Comments are closed.